MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
In this Q&A, Dr. Luis E. Raez and nurse practitioner Beth Sandy discuss recently reported MARIPOSA data in the context of current standard of care and provide best practices for therapeutic selection and patient education. Read more
By Anne-Claire Toffart, MD, PhD, and Jean-François Timsit, MD, PhD Posted: April 1, 2019 Dr. Anne-Claire Toffart Survival rates for patients with lung cancer who were admitted into the intensive care […] Read more
Point/Counterpoint: Why TMB Should or Should Not Be Assessed in Patients with Advanced NSCLC
Posted: April 1, 2019 Why TMB Should Be Assessed in Patients with Advanced NSCLC By Fabrice Barlesi, MD, PhD Dr. Fabrice Barlesi Immune checkpoint inhibitors, especially PD-1 and PD-L1 inhibitors, have […] Read more
Understanding the Effects of Time to Surgery on Upstaging for Stage I Non-Small Cell Lung Cancer
By Russell Bahar, Bsc and Elliot Wakeam, MD, MPH Posted: April 1, 2019 IN REFERENCE TO: Serna-Gallegos DR, et al Effects of time from completed clinical staging to surgery: Does it […] Read more
Nuances of PET Interpretation in Thoracic Oncology: More Than Just Lung Cancer
By Michael MacManus, MD, FRANZCR, and Tim Akhurst, MD, FRACP Posted: March 1, 2019 Dr. Michael MacManus 18F-FDG PET/CT scans portray living biology and are indispensable in thoracic oncologic evaluations, […] Read more
The Vital and Evolving Role of Bronchoscopic Technologies in Lung Cancer Management
By Andrew R. Haas, MD, PhD Posted: October 2018 Lung cancer remains the leading global cause of cancer-related mortality.1 Due to the lack of symptoms at the time early-stage disease […] Read more
By Anne-Marie C. Dingemans, MD, PhD, and Lizza E.L. Hendriks, MD, PhD Posted: October 2018 Patients with stage IV NSCLC are generally viewed as having incurable disease; however, for years, […] Read more
By Edgardo S. Santos Castillero, MD, FACP Posted: October 2018 The approval of osimertinib in the frontline setting for patients with EGFR-sensitizing mutations has immediately challenged the decision-making process for […] Read more
Posted: October 2018 With complete remissions seen in up to 90% of patients with B-cell acute lymphoblastic leukemia (ALL), a breakthrough therapy designation in multiple myeloma, and a first-of-its-kind approval […] Read more
Circulating Tumor Cell–Derived Patient eXplants: A New Tool for SCLC Research
By Caroline Dive, CBE, PhD, FMedSci, and Kris Frese, PhD Posted: August 2018 Small cell lung cancer (SCLC) is aggressive, disseminates early, and has a dismal prognosis.1 Its genomic landscape […] Read more
The IASLC Issues Liquid Biopsy Statement to Aid Understanding of Rapid Innovation
By Joy Curzio Posted: August 2018 Liquid biopsy is a powerful tool that can determine a patient’s molecular tumor profile and aid diagnosis, as well as therapeutic choices. Liquid biopsy […] Read more